Keyphrases
Tositumomab
100%
Relapsed Lymphoma
100%
I-131
100%
Hodgkin Lymphoma
37%
Positron Emission Tomography
25%
Radiation Dose
25%
Complete Response
25%
Hematotoxicity
25%
Total Body Radiation
25%
Positron Emission tomography-CT
25%
Maximum Tolerated Dose
12%
Computed Tomography
12%
Anatomic
12%
Radioimmunotherapy
12%
Therapeutic Effect
12%
Classical Hodgkin Lymphoma
12%
Fluorodeoxyglucose
12%
Response Assessment
12%
Dose Finding
12%
Continual Reassessment Method
12%
Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
12%
Early Metabolic Response
12%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Iodine 131
100%
Tositumomab
100%
Positron Emission Tomography
50%
Fluorine-18
37%
Nodular Lymphocyte Predominant Hodgkin's Lymphoma
37%
Transplantation
25%
Whole Body Radiation
25%
Fluorodeoxyglucose F 18
12%
Therapy Effect
12%
Classical Hodgkin Lymphoma
12%
Radioimmunotherapy
12%
Metabolism
12%
Patient History of Transplantation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Iodine-131
100%
Tositumomab
100%
Fluorine 18
37%
Nodular Lymphocyte Predominant Hodgkin's Lymphoma
37%
Maximum Tolerated Dose
12%
Therapeutic Effect
12%
Classical Hodgkin Lymphoma
12%
Fluorodeoxyglucose F 18
12%
Patient History of Transplantation
12%